xtl biopharmaceuticals ltd. (nasdaq:xtlb, tase:xtlb.ta) is a clinical-stage biotech company focused on the development of pharmaceutical products for the treatment of autoimmune diseases including lupus. the company’s lead drug candidate, hcdr1, is a world-class clinical asset for the treatment of systemic lupus erythematosus (sle). treatments currently on the market for sle are not effective enough for most patients and some have significant side effects. robust clinical data on hcdr1 has been produced in three clinical trials with 400 patients and over 200 preclinical studies with data published in more than 40 peer reviewed scientific journals.
Company profile
Ticker
XTLB
Exchange
Website
CEO
Joshua Levine
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
XTLB stock data
Latest filings (excl ownership)
6-K
Report of Foreign Private Issuer
2 Apr 24
6-K/A
Extraordinary General Meeting of Shareholders
21 Mar 24
6-K
Extraordinary General Meeting of Shareholders
21 Mar 24
6-K
XTL To Aquire The Social Proxy
20 Mar 24
6-K
Report of Foreign Private Issuer
15 Nov 23
6-K
XTL Biopharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
20 Oct 23
6-K
Report of Foreign Private Issuer
10 Aug 23
6-K
Report of Foreign Private Issuer
16 May 23
20-F
2022 FY
Annual report (foreign)
22 Mar 23
6-K
Current report (foreign)
2 Mar 23
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q2 2023
8.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 3 |
Opened positions | 3 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 41.57 mm |
Total shares | 240.26 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Noked Israel | 198.89 k | $199.00 k |
MS Morgan Stanley | 41.17 k | $41.17 mm |
BNP Paribas Arbitrage | 200.00 | $200.00 k |
Proequities | 0.00 | $0.00 |
News
12 Health Care Stocks Moving In Wednesday's Intraday Session
27 Mar 24
Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session
25 Mar 24
12 Health Care Stocks Moving In Monday's Intraday Session
25 Mar 24
12 Health Care Stocks Moving In Wednesday's After-Market Session
20 Mar 24
Dow Surges 350 Points; Fed Holds Rates Steady
20 Mar 24